Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × reolysin × Clear all

Phase

Phase 2 8 Phase 1 5 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anal Cancer Metastatic 1

Interventions

pembrolizumab 241 Carboplatin 134 Nivolumab 131 Gemcitabine 124 Paclitaxel 116 Cisplatin 104 Bevacizumab 95 Cyclophosphamide 90 Dexamethasone 76 Injections 75 Docetaxel 71 Pemetrexed 69 Fluorouracil 68 Capecitabine 64 Rituximab 61 atezolizumab 60 Cetuximab 60 Oxaliplatin 58 130-nm albumin-bound paclitaxel 58 Leucovorin 56 Ipilimumab 51 Lenalidomide 46 fludarabine 42 Azacitidine 40 Irinotecan 39 venetoclax 38 Albumin-Bound Paclitaxel 36 Prednisone 35 Fulvestrant 35 Trastuzumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡